Savaysa (edoxaban) / Daiichi Sankyo - LARVOL DELTA

Thrombotic and Hemorrhagic Adverse Events of Direct Oral Anticoagulants: An Analysis of Sex-Related Differences Using Food and Drug Administration Adverse Event Reporting System. (PubMed, Anatol J Cardiol) - "Significant sex-specific differences exist in DOAC safety profiles. Recognizing these patterns may inform individualized anticoagulant selection and enhance pharmacovigilance-driven personalized medicine."

Adverse events • Journal • Cardiovascular • Cerebral Hemorrhage • CNS Disorders • Hematological Disorders • Ischemic stroke • Myocardial Infarction • Pulmonary Embolism • Respiratory Diseases

DOAC Pharmacologic Interactions in Acute Ischemic/TIA vs Hemorrhagic Stroke: Findings from a 77-Hospital Telestroke Program (ISC 2026) - "DOAC distribution: rivaroxaban 314/446 (70.4%) , apixaban 101/446 (22.6%) , edoxaban 17/446 (3.8%) , dabigatran 14/446 (3.1%) . Cerebrovascular presentations: ischemic stroke 381/446 (85.4%) , non-SAH hemorrhagic stroke 41/446 (9.2%) , SAH 18/446 (4.0%) , TIA 6/446 (1.3%) .Interaction prevalence by event group (pre-specified comparison of ischemic/TIA vs hemorrhagic:Ischemic/TIA (n=387): – PD (bleeding-risk): 130/387 (33.6%) – PK inhibitors (↑ exposure): 37/387 (9.6%) – PK inducers (↓ exposure): 18/387 (4.7%) Hemorrhagic (n=59): – PD (bleeding-risk): 15/59 (25.4%) – PK inhibitors (↑ exposure): 7/59 (11.9%) – PK inducers (↓ exposure): 6/59 (10.2%) PD combinations consistently exceeded PK DDIs overall, driven primarily by acetylsalicylic acid/aspirin and clopidogrel; heparins were less frequent. Among PK interactions, amiodarone predominated as an inhibitor and phenytoin as an inducer. The relative excess of PD DDIs in ischemic/TIA and the higher proportions of PK..."

Clinical • Cardiovascular • Cerebral Hemorrhage • Hematological Disorders • Ischemic stroke

Baseline Characteristics and Preliminary Results of the ADD-ON Registry: A Multicenter Study of Edoxaban With or Without Antiplatelet Therapy in Ischemic Stroke Patients With Atrial Fibrillation and Coexisting Significant Atherosclerosis (ISC 2026) - "The ADD-ON registry provides real-world evidence on antithrombotic strategies in acute patients with AF and atherosclerosis. These patients represent a high-risk population for both ischemic recurrence and bleeding, and forthcoming analyses will help clarify the clinical impact of adding an antiplatelet agent to edoxaban in this challenging setting."

Clinical • Late-breaking abstract • Atherosclerosis • Atrial Fibrillation • Cardiovascular • Diabetes • Hypertension • Ischemic stroke • Metabolic Disorders

Edoxaban for stroke prevention in Chinese patients with atrial fibrillation: 1-year follow-up of the ETNA-AF-China study. (PubMed, Front Pharmacol) - P | "After 1 year, 73.1% patients continued edoxaban use without suspension, discontinuation of edoxaban, or switching to other doses of edoxaban/other NOACs. In a large Chinese AF population, edoxaban showed low incidences of stroke and bleeding, notably major bleeding, ICH, major gastrointestinal bleeding, and CV mortalities, with the majority of patients still on edoxaban at the end of 1-year follow-up."

Journal • Atrial Fibrillation • Cardiovascular • Cerebral Hemorrhage • CNS Disorders • Gastroenterology • Hematological Disorders • Ischemic stroke

Bleeding risk of rivaroxaban and edoxaban with and without amiodarone in atrial fibrillation patients: a prospective cohort study. (PubMed, Eur J Clin Pharmacol) - No abstract available

Journal • Atrial Fibrillation • Cardiovascular

Recurrent Pneumothorax in a Post-pneumonectomy Patient: Surgical Management Under Extracorporeal Membrane Oxygenation Support. (PubMed, Cureus) - "The patient was discharged on postoperative day 12, with a switch to the direct oral anticoagulant edoxaban...Recurrent pneumothorax in a post-pneumonectomy patient represents a high-risk scenario in which conventional ventilation may not safely permit surgery. ECMO-assisted surgery offers a viable option for definitive management in patients with prohibitive pulmonary function."

Journal • Cardiovascular • Chronic Obstructive Pulmonary Disease • Critical care • Hematological Disorders • Immunology • Lung Cancer • Oncology • Pain • Pulmonary Disease • Pulmonary Emphysema • Respiratory Diseases • Solid Tumor • Thrombosis

Direct Oral Anticoagulants for Portal Vein Thrombosis in Cirrhosis: From Pharmacology to Clinical Practice. (PubMed, Clin Appl Thromb Hemost) - "Regulatory guidance supports DOAC use in Child-Turcotte-Pugh (CTP) class A, recommends cautious use in selected CTP class B patients, and generally discourages use in CTP class C. Apixaban and edoxaban show relatively stable pharmacokinetics in compensated cirrhosis. Treatment should be individualized according to liver and renal function, variceal status, and transplant candidacy. High-quality prospective studies are still needed, particularly in CTP classes B/C cirrhosis."

Journal • Review • Cardiovascular • Fibrosis • Hematological Disorders • Immunology • Liver Cirrhosis • Liver Failure • Thrombosis • Transplantation

Impact of postoperative weight loss on anticoagulant dosing after major lower limb amputation. (PubMed, Ann R Coll Surg Engl) - "Major amputation is associated with clinically relevant postoperative weight loss, yet anticoagulant dose adjustments were uncommon. Routine postoperative weight monitoring and prompt review of weight-based therapy are recommended to improve dosing accuracy and reduce potential anticoagulation risk."

Journal

Direct Oral Anticoagulants for Cancer-Associated Venous Thromboembolism in Hematologic Malignancies: A Comprehensive Review. (PubMed, Eur J Haematol) - "Direct oral anticoagulants (DOACs), including factor Xa inhibitors (apixaban, rivaroxaban, edoxaban) and thrombin inhibitors (dabigatran), have emerged as appealing alternatives due to their ease of use, predictable pharmacokinetics, and reduced monitoring requirements. It emphasizes individualized anticoagulation strategies, highlights existing evidence gaps, and outlines future research priorities, particularly the safe application of DOACs in severe thrombocytopenia and interactions with targeted therapies. Ultimately, tailored anticoagulant approaches are essential to optimizing patient outcomes in this complex patient population."

Journal • Review • Cardiovascular • Hematological Disorders • Hematological Malignancies • Leukemia • Lymphoma • Multiple Myeloma • Myeloproliferative Neoplasm • Oncology • Thrombocytopenia • Venous Thromboembolism

Heparin-Induced Thrombocytopenia in a Patient With Postoperative Pulmonary Embolism: D-dimer Re-elevation and Progressive Pulmonary Artery Thrombosis. (PubMed, Cureus) - "Argatroban was later replaced with edoxaban after platelet recovery. Clinicians should maintain a high index of suspicion for HIT in heparin-treated patients presenting with thrombocytopenia, with supportive laboratory findings such as unexpected D-dimer elevation, even in the absence of new or worsening symptoms. Early recognition and prompt management are essential to improve outcomes and prevent severe complications or death."

Journal • Cardiovascular • Hematological Disorders • Pulmonary Embolism • Respiratory Diseases • Thrombocytopenia • Venous Thromboembolism

Direct oral anticoagulant interference and removal in the factor VIII inhibitor assay. (PubMed, Res Pract Thromb Haemost) - "Normal pooled plasma was spiked with therapeutic and supratherapeutic concentrations of apixaban, edoxaban, rivaroxaban, and dabigatran. Activated charcoal-based DOAC removal treatment provides a practical solution to restore assay reliability. These findings support the integration of DOAC removal into anti-FVIII testing protocols for patients on anticoagulant therapy."

Journal • Hematological Disorders • Hemophilia • Hemophilia A • Rare Diseases

Subclinical atrial fibrillation: Implications of recent trials for guideline updates? (PubMed, World J Cardiol) - "Previous randomized trials of direct oral anticoagulants (DOACs) in patients with cryptogenic stroke-NAVIGATE-ESUS (with rivaroxaban) and RE-SPECT ESUS (using dabigatran)-failed to demonstrate superiority over aspirin. More recently, two dedicated studies in SCAF with DOACs have been published: NOAH-AFNET 6 (with edoxaban) and ARTESIA (with apixaban)...For those with high bleeding risk, re-evaluation after optimizing modifiable bleeding risk factors (e.g., concomitant medications, blood pressure control) may help determine eligibility for anticoagulation. Ongoing large-scale DOAC trials will further clarify this contentious issue."

Journal • Review • Atrial Fibrillation • Cardiovascular • Endocrine Disorders • Hypertension

Factors influencing the inappropriate dosing of rivaroxaban and edoxaban in Chinese hospitalized patients with atrial fibrillation. (PubMed, Front Cardiovasc Med) - "Inappropriate dosing of direct oral anticoagulants (DOACs) may increase the risk of thromboembolism or bleeding in patients with atrial fibrillation (AF). The incidence of inappropriate DOAC dosing in Chinese patients with AF was high. Advanced age, the concurrent use of antiplatelet medications, and the nonuse of dronedarone have been identified as independent factors associated with inappropriate dosing."

Journal • Atrial Fibrillation • Cardiovascular

Hemorrhagic risk of concomitant direct oral anticoagulants and fluoroquinolones: integration of pharmacovigilance and therapeutic drug monitoring. (PubMed, Front Pharmacol) - "ROR = 4.68, 95% CI: 3.41-6.55), particularly levofloxacin (adj. ROR = 6.12) and ciprofloxacin (adj...No significant signals were found for rivaroxaban, apixaban, or edoxaban...Other DOACs appear safer with FQNs coadministration. For dabigatran patients requiring FQNs, alternative agents or enhanced monitoring should be considered."

Adverse events • Journal • Hematological Disorders

Reduced Versus Full-Dose Direct Oral Anticoagulants for Long-Term Management of Venous Thromboembolism: A Systematic Review. (PubMed, J Clin Med) - " A systematic search of PubMed and the Cochrane Library (January 2010-November 2025) identified randomized trials and one ambispective cohort study evaluating reduced-dose apixaban (2.5 mg BID), rivaroxaban (10 mg OD), dabigatran (110 mg BID), or edoxaban (30 mg OD)...Across trials, reduced-dose DOACs maintained consistently low rates of recurrent VTE: 1.7% in AMPLIFY-EXT versus 8.8% with placebo; 1.2-1.5% in EINSTEIN CHOICE versus 4.4% with aspirin; 2.2% in RENOVE versus 1.8% with full-dose therapy; and 1.3% in HI-PRO versus 10% with placebo... In summary, reduced-dose DOACs appear to offer a favorable balance of safety and efficacy, providing durable protection against recurrence with a lower bleeding burden. These findings support their role as a practical extended-treatment strategy in clinical practice."

Journal • Review • Cardiovascular • Venous Thromboembolism

Temporal Trends in the Use of Direct Oral Anticoagulants Prior to Stroke Admission. (PubMed, J Stroke Cerebrovasc Dis) - "The proportion of patients on DOACs at admission doubled between 2015 and 2023. Patients on DOACs were older, had more comorbidities. Patients with ICH on DOAC prior to admission were more likely to have died during their hospitalization or be discharged to long-term care."

Journal • Cardiovascular • Cerebral Hemorrhage • Ischemic stroke

From Clot Prevention to Kidney Injury: Revisiting Anticoagulant-Related Nephropathy. (PubMed, Kidney Blood Press Res) - "Anticoagulant-related nephropathy (ARN) is a serious and often underdiagnosed complication of anticoagulant therapy, particularly associated with vitamin K antagonists, such as warfarin, and more recently, with direct oral anticoagulants (DOACs), including dabigatran, rivaroxaban, edoxaban, and apixaban. Despite various treatment approaches, ranging from withdrawal of anticoagulation to supportive therapy and corticosteroids, no definitive treatment exists. This review discusses the epidemiology, pathogenesis, diagnosis, and treatment of ARN."

Journal • Review • Acute Kidney Injury • Chronic Kidney Disease • Hematological Disorders • Nephrology • Renal Disease

Intracerebral Hemorrhage During the Chronic Phase of Eosinophilic Granulomatosis With Polyangiitis: A Case Report Emphasizing Cerebrovascular Vulnerability. (PubMed, Clin Case Rep) - "After receiving high-dose corticosteroids (Day-165) and edoxaban for subacute distal deep vein thrombosis (Day-158), her eosinophil count steadily decreased, and she was discharged without hypertension on oral prednisolone 40 mg/day (Day-144). Current guidelines do not address this risk, underscoring the need for individualized risk assessment. This case may indicate that brain imaging, including SWI, could be considered prior to initiating anticoagulation therapy in patients with EGPA."

Journal • Asthma • Cardiovascular • Cerebral Hemorrhage • Eosinophilia • Eosinophilic Granulomatosis With Polyangiitis • Hematological Disorders • Hypertension • Immunology • Inflammation • Langerhans Cell Histiocytosis • Pulmonary Disease • Rare Diseases • Respiratory Diseases • Rheumatology • Thrombosis • Vasculitis

Comparing survival with vitamin K antagonists, low-molecular-weight heparin, and direct oral anticoagulants in patients with cancer-a systematic review and meta-analysis. (PubMed, Res Pract Thromb Haemost) - "The use of VKA was associated with lower mortality than non-VKA anticoagulation in patients with cancer in observational studies but not in randomized trials. The analysis was limited by high heterogeneity, which must be considered when interpreting results."

Journal • Retrospective data • Cardiovascular • Hematological Disorders • Oncology • Solid Tumor • Thrombosis • Venous Thromboembolism

Dabigatran and Edoxaban in the Repair of an Abnormal Cleft in the Right Wall of the Ascending Aorta: A Case Report. (PubMed, Cureus) - "In this case report, linear white (high echo intensity) thrombi extending from the right upper pulmonary vein (RUPV) penetrated the wall of the ascending aorta (AAo), resulting in a cleft in the AAo wall in an area with possible medial degeneration. Additionally, we show that dabigatran and edoxaban partially resolved the linear thrombi and cured the cleft."

Journal • Atherosclerosis • Cardiovascular

Direct Oral Anticoagulants for Treating Fibrin Sheath-induced Central Venous Port System Dysfunction. (PubMed, Interv Radiol (Higashimatsuyama)) - "All patients received edoxaban as direct oral anticoagulant, at doses of 30 mg (n = 3) or 60 mg (n = 6) based on their body weights...No recurrence of fibrin sheath-induced central venous port system dysfunction was observed during the mean follow-up period of 133 ± 98 days. Direct oral anticoagulant administration can be a potentially effective and safe strategy for managing fibrin sheath-induced central venous port system dysfunction formation."

Journal

DABI-SNAP: Dabigatran for the Adjunctive Treatment of Staphylococcus Aureus Bacteremia (clinicaltrials.gov) - P4 | N=300 | Recruiting | Sponsor: Emily McDonald | Trial completion date: Jan 2029 ➔ Jan 2030 | Trial primary completion date: Jan 2029 ➔ Jan 2030 | Not yet recruiting ➔ Recruiting

Enrollment open • Trial completion date • Trial primary completion date • Cardiovascular • Infectious Disease

Use of direct oral anticoagulants (DOACs) in oncology: A phase IV study on impact of edoxaban treatment in Italian patients with cancer with venous thromboembolism during antineoplastic therapy (EDOI trial, GOIRC 05-2018). (ASCO 2023) - P4 | "The results of the study clearly show that the edoxaban treatment is well tolerated and has no relevant impact on the delivery of cancer treatments. Results in terms of quality of life and patients’ satisfaction with anticoagulant treatment are reassuring. Clinical trial information: EUDRACT 2018-003833-14."

Clinical • P4 data • Anemia • Cardiovascular • Hematological Disorders • Hepatology • Immunology • Oncology • Venous Thromboembolism

VICTORIE: Anticoagulation in Patients With Venous Thromboembolism and Cancer (clinicaltrials.gov) - P=N/A | N=1 | Active, not recruiting | Sponsor: Pfizer | Trial completion date: Dec 2025 ➔ Apr 2026 | Trial primary completion date: Dec 2025 ➔ Apr 2026

Trial completion date • Trial primary completion date • Cardiovascular • Oncology • Venous Thromboembolism

Underdosed Edoxaban and Clinical Outcomes in Patients with Non-valvular Atrial Fibrillation in Real World: A Retrospective Cohort Study. (PubMed, Clin Appl Thromb Hemost) - "Compared with the recommended dose, this dosing strategy was associated with comparable risks of IS/SE and major bleeding, as well as a potentially lower incidence of CRNM bleeding. These findings should be considered preliminary and warrant validation in larger, multi-center prospective studies."

Clinical data • Journal • Real-world evidence • Retrospective data • Atrial Fibrillation • Cardiovascular • Ischemic stroke